Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 13Breast 6Head & Neck 3Thoracic 1Sarcoma 1Myeloid 1Gastrointestinal 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 6874Lung Neoplasms 5105Small Cell Lung Carcinoma 1166Breast Neoplasms 855Neoplasms 762Colorectal Neoplasms 670Melanoma 566Ovarian Neoplasms 506Neoplasm Metastasis 481Pancreatic Neoplasms 473Adenocarcinoma of Lung 398Stomach Neoplasms 396Prostatic Neoplasms 370Head and Neck Neoplasms 368Carcinoma, Renal Cell 350Esophageal Neoplasms 337Squamous Cell Carcinoma of Head and Neck 325Mesothelioma, Malignant 324Colonic Neoplasms 294Mesothelioma 289Urinary Bladder Neoplasms 262Brain Neoplasms 254Uterine Cervical Neoplasms 243Triple Negative Breast Neoplasms 223Sarcoma 198Endometrial Neoplasms 196Carcinoma, Hepatocellular 186NSCLC 167Pleural Effusion, Malignant 160Kidney Neoplasms 160

Interventions

apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bulbo-Spinal Atrophy, X-Linked × Thoracic × Clear all
NCT04926181 2025-05-15

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
2 enrolled 12 charts
GenitourinaryThoracic

Prostatic Neoplasms, Carcinoma, Small Cell, Bulbo-Spinal Atrophy, X-Linked, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡